Patents by Inventor Jan van de Winkel

Jan van de Winkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES AGAINST C-MET
    Publication number: 20150329642
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: May 26, 2015
    Publication date: November 19, 2015
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
  • Antibodies against CD38 for treatment of multiple myeloma
    Patent number: 9187565
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: November 17, 2015
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Human antibody drug conjugates against tissue factor
    Patent number: 9168314
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 27, 2015
    Assignee: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Human antibodies against tissue factor and methods of use thereof
    Patent number: 9150658
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: October 6, 2015
    Assignee: GENMAB A/S
    Inventors: Sandra Verploegen, David P. E. Satijn, Rene Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N. De Jong
  • Heterodimeric antibody Fc-containing proteins and methods for production thereof
    Patent number: 9150663
    Abstract: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: October 6, 2015
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS
    Publication number: 20150231235
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: December 10, 2014
    Publication date: August 20, 2015
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Yvo GRAUS, Judith OPRINS, Michel DE WEERS, Martine VAN VUGT, Ole BAADSGAARD, D.M.Sc., Steen LISBY
  • Anti-OX40L antibodies
    Patent number: 9102733
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: August 11, 2015
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Monoclonal antibodies against c-Met
    Patent number: 9068011
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: June 30, 2015
    Assignee: GENMAB A+S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Combination treatment of CD38-expressing tumors
    Patent number: 9040050
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: May 26, 2015
    Assignee: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • MONOCLONAL ANTIBODIES AGAINST CD32B
    Publication number: 20150004177
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 1, 2015
    Inventors: Edward Norbert VAN DEN BRINK, Paul PARREN, Jan VAN DE WINKEL, Aran Frank LABRIJN, Frank Everhardus Martinus REBERS, Esther Cornelia Wilhelmina BREIJ
  • NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER
    Publication number: 20140348833
    Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.
    Type: Application
    Filed: March 6, 2014
    Publication date: November 27, 2014
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Willem Karel BLEEKER, Klaus EDVARDSEN, Jeroen Lammerts VAN BUEREN, Thomas VALERIUS, Michael DECHANT, Wencke WEISNER, Sven BERGER
  • Monoclonal antibodies against CD32B
    Patent number: 8802089
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: August 12, 2014
    Assignee: Genmab A/S
    Inventors: Edward Norbert Van Den Brink, Paul Parren, Jan Van De Winkel, Aran Frank Labrijn, Frank Everhardus Martinus Rebers, Esther Cornelia Wilhelmina Breij
  • STABLE IGG4 ANTIBODIES
    Publication number: 20130345406
    Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Application
    Filed: June 7, 2013
    Publication date: December 26, 2013
    Applicant: GENMAB A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
  • MONOCLONAL ANTIBODIES AGAINST C-MET
    Publication number: 20130216548
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: March 10, 2011
    Publication date: August 22, 2013
    Applicant: GENMAB A/S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • ANTIBODIES AGAINST HUMAN CD38
    Publication number: 20130209355
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 8, 2011
    Publication date: August 15, 2013
    Applicant: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20130189271
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: May 27, 2011
    Publication date: July 25, 2013
    Applicant: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce I. Meesters, Janine Schuurman, Edward Norbert Van Den Brink
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE
    Publication number: 20130171148
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: May 27, 2011
    Publication date: July 4, 2013
    Applicant: GENMAB A/S
    Inventors: Bart De Goeij, Edward Norbert Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20130101608
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: June 15, 2011
    Publication date: April 25, 2013
    Applicant: GENMAB A/S
    Inventors: David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren
  • Nucleic acid molecules encoding anti-P-selectin antibodies
    Patent number: RE44359
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: July 9, 2013
    Assignee: Hoffmann-La Roche Inc
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies
    Patent number: RE44389
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: July 23, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt